IMDZ News
Archived Headlines
- Immune Design prices IPO at $12, the low end of the range 07/24/14
- Immunotherapy biotech Tobira Therapeutics sets terms for $60 million IPO; researching HIV and NASH 07/21/14
- 14 US IPOs planned for the week of Jul 21 07/21/14
- Immuno-oncology biotech Immune Design sets terms for $60 million IPO 07/14/14
- Immuno-oncology biotech Immune Design files for a $60 million IPO 06/23/14
Cancer biotech Bellicum Pharmaceuticals files for a $115 million IPO
Bellicum Pharmaceuticals, which is developing adjunct cancer immunotherapies based on a conditionally responsive platform, filed on Tuesday with the SEC to raise up to $115 million in an initial public offering. 2014 has seen a rush of biotech IPOs,...read more
The next big cancer biotech: Juno Therapeutics files for a $150 million IPO
Juno Therapeutics, which is developing immunotherapy treatments for hematologic and solid tumor cancers, filed on Monday with the SEC to raise up to $150 million in an initial public offering. The year's largest biotechs by deal size (FWP; $221 million)...read more
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat
This week's 10 IPOs largely disappointed as 70% were forced to price below the proposed range and 80% closed the week up 1% or less. Before this week, only 36% of IPOs this year had first-day pops of 1% or less. The enthusiasm for last week's ...read more
Thursday saw four IPOs raise under $100 million; two broke issue
Two of the four IPOs on Thursday broke issue after pricing below the range. Less than a quarter of IPOs in the past three months have traded down on the first day. The top performer, Intersect ENT (XENT), priced at the low end and gained 18%. The...read more